Towards the eradication of HPV infection through universal specific vaccination

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Crosignani, Piergiorgio ^a   De Stefani, Antonella ^b   Fara, Gaetano Maria ^c   Isidori, Andrea M ^d   Lenzi, Andrea ^d   Liverani, Carlo Antonio ^a   Lombardi, Alberto ^e   Mennini, Francesco Saverio ^d,f,g   Palu', Giorgio ^h   Pecorelli, Sergio ⁱ   Peracino, Andrea P ^e,j   Signorelli, Carlo ^k   Zuccotti, Gian Vincenzo ^l  

^a UNIVERSITY OF MILAN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Fondazione Giovanni Lorenzini Medical Science Foundation   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g KINGSTON UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j Giovanni Lorenzini Medical Foundation   (United States)

^k UNIVERSITY OF PARMA   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Anti HPV vaccines; Cervical cancer; Condylomas; Genital cancer; HPV infection; Incremental cost effectiveness ratio; Oro pharyngeal cancer; Universal vaccination; Vaccination programs

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; DISEASE ERADICATION; FEMALE; HEALTH; HEALTH CARE QUALITY; HUMAN; MALE; METHODOLOGY; PAPILLOMAVIRUS INFECTION; PREVENTIVE HEALTH SERVICE; REVIEW;

ADOLESCENT; ADULT; DISEASE ERADICATION; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGRAM EVALUATION; WORLD HEALTH; YOUNG ADULT;

EID: 84880023249     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-642     Document Type: Article

References (111)

1. The epidemiology of human papilloma virus infections. Baseman JG, Koutsky LA, J Clin Virol 2005 32 Suppl 1 16 S24 15753008
2. Papillomavirus vaccines in perspective. Kahn JA, Burk RD, Lancet 2007 369 2135 2137 10.1016/S0140-6736(07)60947-7 17602733
3. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S, J Infect Dis 2010 202 12 1789 1799 10.1086/657321 21067372
4. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland. Syrjanen KJ, Scand J Infect Dis Suppl 2009 108 2 32 19939209
5. Papillomavirus infections and human genital cancer. Zur Hausen H, de Villiers EM, Gissmann L, Gynecol Oncol 1981 12 124 S128 10.1016/0090-8258(81) 90067-6 6273261
6. The search for infectious causes of human cancers where and why. Zur Hausen H, Virology 2009 392 1 1 10 10.1016/j.virol.2009.06.001 19720205
7. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Tota J, Chevarie-Davis M, Richardson LA, Devries M, Franco EL, Prev Med 2011 53 12 S21 21962466
8. Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know. Genden EM, Sambur IM, de Almeida JR, Posner M, Rinaldo A, Rodrigo JP, Strojan P, Takes RP, Ferlito A, Eur Arch Otorhinolaryngol 2013 270 2 405 416 10.1007/s00405-012-2086-4 22752642
9. Human papillomavirus in infants: transmission, prevalence, and persistence. LaCour DE, Trimble C, J Pediatr Adolesc Gynecol 2012 25 93 97 10.1016/j.jpag.2011.03.001 21600804
10. Anogenital human papillomavirus in sexually abused and non abused children: a multicenter study. Unger ER, Fajman NN, Maloney EM, Onyekwuluje J, Swan DC, Howard L, Beck-Sague CM, Sawyer MK, Girardet RG, Sautter RL, Hammerschlag MR, Black CM, Pediatrics 2011 128 3 658 e665 21844060
11. Nonsexual transmission of anogenital warts in children: a retrospective analysis. Jones V, Smith SJ, Omar HA, ScientificWorldJournal 2007 7 1896 1899 18060328
12. Ano-genital in children: sexual abuse or not? Honor G, J Pediatr Health Care 2004 18 4 165 170 15224040
13. Hand-genital transmission of genital warts? An analysis of prevalence data. Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM, Epidemiol Infect 1995 115 169 176 10.1017/S0950268800058234 7641831
14. Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sonnex C, Strauss S, Gray JJ, Sex Transm Inf 1999 75 317 319 10.1136/sti.75.5.317
15. Detection of genital HPV types in fingertip samples from newly sexually active female university students. Rachel L, Winer RL, Hughes JP, Feng Q, Fu Xi L, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA, Cancer Epidemiol Biomarkers Prev 2010 19 7 1682 1685 10.1158/1055-9965.EPI-10-0226 20570905
16. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM, Lancet 2011 377 2085 2092 10.1016/S0140-6736(11)60551-5 21684381
17. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, Fairley CK, Guy RJ, BMJ 2013 346 2032 Published 19 April 2013 10.1136/bmj.f2032 23599298
18. Morbidity and Mortality Weekly Reports. MMWR 2012 61 No.15 258 261 http://www.cdc.gov/mmwr/pdf/wk/mm6115.pdf 22513527
19. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsaguè X, BMC Cancer 2012 12 30 10.1186/1471-2407-12-30 22260541
20. The known unknowns of HPV natural history. Gravitt PE, J Clin Invest 2011 121 12 4593 4599 10.1172/JCI57149 22133884
21. Prevention of cervical cancer through papillomavirus vaccination. Frazer IH, Nature Rev Immunol 2004 4 46 55 10.1038/nri1260
22. Human papillomavirus and cervical cancer. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S, Lancet 2007 370 9590 890 907 10.1016/S0140-6736(07)61416-0 17826171
23. Measuring serum antibody to human papillomavirus following infection or vaccination. Frazer IH, Gynecol Oncol 2010 118 Issue 1, Supplement 1 8 S11 20494221
24. Epidemiology and natural history of human papillomavirus infection in women from a high-risk area of cervical cancer. Franco E, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE, J Infect Dis 1999 80 5 1415 1423
25. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS, Lancet 2001 357 9271 1831 1836 10.1016/S0140-6736(00)04956-4 11410191
26. Case records of the Massachusetts General Hospital. Case 10-2009. A 23-year-old woman with an abnormal Papanicolaou smear. Goldstein MA, Goodman A, del Carmen MG, Wilbur DC, NEJM 2009 360 13 1337 1344 10.1056/NEJMcpc0810837 19321871
27. Epidemiology of human papilloma virus infection in men, cancers other than cervical and benign conditions. Giuliano AR, Tortelero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX, Vaccine 2008 26 Suppl 10 17 K28 18847554
28. The spectrum and clinical sequelae of human papillomavirus infection. Monk BJ, Tewari KS, Nov Gynecol Oncol 2007 107 2 Suppl 1 6 S13
29. Molecular analyses and prognostic relevance of HPV in head and neck tumours. Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi SS, Vigili MG, Venuti A, Oncol Rep 2007 17 931 939 17342339
30. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister H, Fuchs PG, Cancer 2001 92 2875 2884 10.1002/1097-0142(20011201)92:11<2875::AID-CNCR10130>3. 0.CO;2-7 11753961
31. Prevalence and characteristics of HPV infection in oropharyngeal cancer. De Stefani A, Boffano P, Averono G, Ramella A, Pia F, Bongioannini G, J Craniofac Surg 2013 24 1 40 e43 10.1097/SCS.0b013e31826cfffa 23348332
32. Mucosal junctions: open doors for HPV and HIV infections? Herfs M, Hubert P, Moutschen M, Delvenne P, Trends Microbiol 2011 19 114 120 10.1016/j.tim.2010.12.006 21216598
33. The human papillomavirus infection in Men (HIM) study: HPV prevalence and type-distribution among men residing in Brazil, Mexico, and the US. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, Papenfuss MR, Abrahamsen M, Jolles E, Nielson CM, Baggio ML, Silva R, Quiterio M, Cancer Epidemiol Biomarkers Prev 2008 17 8 2036 2043 10.1158/1055-9965.EPI-08-0151 18708396
34. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED Jr, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, Garner EI, Guris D, J Infect Dis 2011 203 58 65 10.1093/infdis/jiq015 21148497
35. The association of hormonal contraceptive use and HPV prevalence. Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A, Phongnarisorn C, Wootipoom V, Yuenyao P, Vipupinyo C, Rugpao S, Sriplienchan S, Celentano DD, Int J Cancer 2011 128 12 2962 2970 10.1002/ijc.25628 20734390
36. Tobacco and alcohol use increase the risk of both HPV associated and HPV independent head and neck cancers. Smith E, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP, Cancer Causes Control 2010 21 1369 1378 10.1007/s10552-010-9564-z 20401530
37. Condom use and the risk of genital human papillomavirus infection in young women. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA, NEJM 2006 354 25 2645 2654 10.1056/NEJMoa053284 16790697
38. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai. Wawer MJ, Tobian AA, Kigozi G, Kong X, Gravitt PE, Serwadda D, Nalugoda F, Makumbi F, Ssempiija V, Sewankambo N, Watya S, Eaton KP, Oliver AE, Chen MZ, Reynolds SJ, Quinn TC, Gray RH, Uganda. Lancet 2011 377 9761 209 218
39. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, Charvat B, Ssempijja V, Riedesel M, Oliver AE, Nowak RG, Moulton LH, Chen MZ, Reynolds SJ, Wawer MJ, Gray RH, NEJM 2009 360 13 1298 1309 10.1056/NEJMoa0802556 19321868
40. Age-specific prevalence of infection with human papillomavirus in females: a global review. Smith JS, Melendy A, Rana RK, Pimenta JM, J Adolesc Health 2008 43 5 S25 18809145
41. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D, Lancet 2011 377 932 940 10.1016/S0140-6736(10)62342-2 21367446
42. Age-specific prevalence of human papilloma virus infection in males: a global review. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM, J Adolesc Health 2011 48 540 552 10.1016/j.jadohealth.2011.03.010 21575812
43. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R, J Clin Microbiol 1995 33 8 2058 2063 7559948
44. Genital warts and risk of cancer-a Danish study of nearly 50,000 patients with genital warts. Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK, J Infect Dis 2012 205 10 1544 1553 10.1093/infdis/jis228 22427679
45. Cancers attributable to human papillomavirus infection. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J, Sex Health 2010 7 244 252 10.1071/SH10020 20719211
46. WHO/ICO Information Centre, Human Papillomavirus and Related Cancers. Summary Report Update EUROPE Summary Report Update. 2010 http://www.who.int/ hpvcentre
47. Economic burden of human papillomavirus-related diseases in Italy. Baio GL, Capone A, Marcellusi A, Mennini FS, Favato G, PLoS One 2012 7 11 49699 10.1371/journal.pone.0049699 23185412
48. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Vajdic CM, van Leeuwen MT, Jin F, Prestage G, Medley G, Hillman RJ, Stevens MP, Botes LP, Zablotska I, Tabrizi SN, Grulich AE, Sex Transm Infect 2009 85 330 335 10.1136/sti.2008.034744 19342375
49. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky JM, J Infect Dis 2004 190 2070 2076 10.1086/425906 15551204
50. Human papillomavirus infection in men who have sex with men participating in a Dutch gay-cohort study. Van der Snoek EM, Niesters HG, Mulder PG, van Doornum GJ, Osterhaus AD, van der Meijden WI, Sex Transm Dis 2003 30 639 644 10.1097/01.OLQ.0000079520.04451.59 12897686
51. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L, NEJM 1987 317 973 977 10.1056/NEJM198710153171601 2821396
52. Correlates of homosexual behavior and the incidence of anal cancer. Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R, JAMA 1982 247 1988 1990 10.1001/jama.1982.03320390050042 7062503
53. Genital warts incidence and healthcare resource utilisation in Australia. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S, Sex Transm Infect 2010 86 181 186 10.1136/sti.2009.040188 19965802
54. Cervarix: Summary of Product Characteristics http://www.medicines.org.uk/ emc/medicine/20204/SPC/Cervarix
55. Gardasil: Summary of Product Characteristics http://www.medicines.org.uk/ emc/medicine/19016/SPC/gardasil/
56. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D, NEJM 2011 364 5 401 411 10.1056/NEJMoa0909537 21288094
57. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. Palefsky J, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI, NEJM 2011 365 1576 1585 10.1056/NEJMoa1010971 22029979
58. A case assignment methodology for determining quadrivalent HPV vaccine efficacy against AIN in men having sex with men. Goldstone S, 26th International Papillomavirus Conference Montreal, Canada 2010 http://www.eurogin.com/2010/ EUROGIN2010-Abstracts.pdf
59. Efficacy and safety of prophylactic vaccines against cervical HPV infection and disease among women: a systematic review & meta-analysis. Lu B, Lu B, Kumar A, Castellsagué X, Giuliano AR, BMC Infect Dis 2011 11 13 10.1186/1471-2334-11-13 21226933
60. Evidence of immune memory 8,5 years following administration of a prophylactic human papillomavirus type 16 vaccine. Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS, Koutsky LA, J Clin Virol 2012 53 3 239 243 10.1016/j.jcv.2011.12.009 22209292
61. An evaluation of the Long-term effectiveness, immunogenicity and safety of Gardasil™ Kjaer SK, EUROGIN 2011 http://www.eurogin.com/2011/Eurogin- 2011-Abstracts.pdf
62. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A, GlaxoSmithKline Vaccine HPV-007 Study Group, Lancet 2009 374 9706 1975 1985 19962185
63. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA, Vaccine 2007 25 4324 4333 10.1016/j.vaccine.2007.02.069 17445955
64. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS, Protocol 016 Study Group, Pediatrics 2006 118 5 2135 2145 10.1542/peds.2006-0461 17079588
65. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6,11,16,18) L1 viral like particle vaccine in older adolescents and young adults. Moreira ED Jr, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, Hillman RJ, Ferris D, Coutlee F, Vardas E, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI, Hum Vaccin 2011 7 7 768 775 10.4161/hv.7.7.15579 21712645
66. Clinical trial and postlicensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS, Pediatr Infect Dis J 2010 29 95 101 10.1097/INF.0b013e3181b77906 19952863
67. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD® Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM, Vaccine 2010 28 4719 4730 10.1016/j.vaccine.2010.04.070 20451636
68. Impact of the human papillomavirus vaccine on genital wart diagnoses at Auckland Sexual Health Services. Oliphant J, Perkins N, NZMJ 2011 124 1339 51 58
69. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Bauer HM, Wright G, Chow J, Am J Public Health 2012 102 5 833 835 10.2105/AJPH.2011.300465 22420808
70. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS, Sex Transm Infect 2009 85 7 499 502 10.1136/sti.2009.037788 19837728
71. What can surveillance of genital warts tell us ? Fairley CK, Donovan B, Sex Health 2010 7 3 325 327 10.1071/SH09145 20719222
72. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, D'Ancona F, Lévy-Bruhl D, on behalf of the VENICE 2 project gatekeepers group, Euro Surveill 2010 15 47 Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19730
73. Morbidity and mortality weekly report (MMRW) adult vaccination coverage-United states 2010. 2012 61 04 66 72 http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm6104a2.htm
74. Recommendations on the use of quadrivalent human papillomavirus vaccine in males. Advisory Committee on Immunization Practices (ACIP), MMRW 2011 60 50 1707 1708
75. HPV vaccine recommendations. American academy of paediatrics. Brady MT, Byington CL, Davies HD, Edwards KM, Glode MP, Jackson MA, Keyserling HL, Maldonado YA, Murray DL, Orenstein WA, Schutze GE, Willoughby RE, Zaoutis TE, Pediatrics 2012 129 3 602 605 22371460
76. Australian Government. Department of Health and Ageing. Immunise Australia Program. Human papillomavirus (HPV). Australian Government [Accessed 31 July 2011]. [ http://www.immunise.health.gov.au/internet/immunise/publishing. nsf/Content/immunise-hpv ]
77. Measuring human papillomavirus (HPV) vaccination coverage and the role of the national HPV vaccination program register. Gertig DM, Brotherton JM, Saville M, Australia. Sex Health 2011 8 2 171 178 10.1071/SH10001
78. National Advisory Committee on Immunization (NACI). Update on Human Papillomavirus (HPV) Vaccines. An Advisory Committee Statement (ACS), Canada Comunicable Disease Report (CCDR) 2012 37 1 62
79. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Jit M, Choi YH, Edmunds WJ, BMJ 2008 337 769 10.1136/bmj.a769 18640957
80. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Kim JJ, Goldie SJ, BMJ 2009 339 3884 10.1136/bmj.b3884 19815582
81. Evaluating human papillomavirus vaccination programs. Taira AV, Neukermans CP, Sanders GD, Emerg Infect Dis 2004 10 1915 1923 10.3201/eid1011.040222 15550200
82. Cost-effectiveness of human papillomavirus vaccination in the United States. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE, Emerg Infect Dis 2008 14 2 244 251 10.3201/eid1402.070499 18258117
83. Health and economic implications of HPV vaccination in the United States. Kim JJ, Goldie SJ, NEJM 2008 359 821 832 10.1056/NEJMsa0707052 18716299
84. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N, Gynecol Oncol 2009 112 370 376 10.1016/j.ygyno.2008.09.031 19041125
85. Model for assessing human papillomavirus vaccination strategies. Elbasha EH, Dasbach EJ, Insinga RP, Emerg Infect Dis 2007 13 28 41 10.3201/eid1301. 060438 17370513
86. Favato G, Pieri V, Mills R, Cost-effective analysis of anti-HPV vaccination programme in Italy: a multi-cohort Markov model 2007 Available at SSRN: http://ssrn.com/abstract=961847 or http://dx.doi.org/10.2139/ssrn.961847
87. Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases. Favato G, Baio G, Capone A, Marcellusi A, Costa S, Garganese G, Picardo M, Drummond M, Jonsson B, Scambia G, Zweifel P, Mennini FS, Med Care 2012 50 12 1076 1085 10.1097/MLR.0b013e318269e06d 22922435
88. National institute for clinical excellence and its value judgments. Rawlins MD, Culyer AJ, BMJ 2004 329 7459 224 227 10.1136/bmj.329.7459.224 15271836
89. Anti-HPV vaccination: a review of recent economic data for Italy. Mennini FS, Costa S, Favato G, Picardo M, Vaccine 2009 27 54 A61 19480963
90. The Australian model of immunization advice and vaccine funding. Nolan TM, Vaccine 2010 28 76 A83 20413003
91. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical cancer screening program. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G, Sex Health 2007 4 165 175 10.1071/SH07043 17931529
92. Impact of vaccinating boys and men against HPV in the United States. Elbasha EH, Dasbach EJ, Vaccine 2010 28 6858 6867 10.1016/j.vaccine.2010.08.030 20713101
93. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC, J Infect Dis 2011 204 3 372 376 10.1093/infdis/jir285 21742835
94. Sexual behaviors, relationships, and perceived health among adult men in the United States: results from a national probability sample. Reece M, Herbenick D, Schick V, Sanders SA, Dodge B, Fortenberry JD, J Sex Med 2010 7 Suppl 5 291 304 21029386
95. ECDC guidance. Introduction of HPV vaccines in European Union countries-an update http://www.ecdc.europa.eu
96. Rome consensus conference-statement; human papilloma virus diseases in males. Lenzi A, Mirone V, Gentile V, Bartoletti R, Ficarra V, Foresta C, Mariani L, Mazzoli S, Parisi SG, Perino A, Picardo M, Zotti CM, BMC Publ Health 2013 13 117 10.1186/1471-2458-13-117
97. Prevalence of anal cytological abnormalities in women with positive cervical cytology. Calore EE, Giaccio CM, Nadal SR, Diagn Cytopathol 2011 39 5 323 327 10.1002/dc.21386 21488174
98. Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females. Weiss TW, Zimet GD, Rosenthal SL, Brenneman SK, Klein JD, J Adolesc Health 2010 47 1 3 11 10.1016/j.jadohealth.2010.03.003 20547286
99. Human papillomavirus-related disease in men: not just a women's issue. Palefsky JM, J Adolesc Health 2010 46 4 Suppl 12 S19 20307839
100. Some straight talk about anal human papillomavirus infection. Goldstone SE, J Infect Dis 2010 201 10 1450 1452 10.1086/652188 20367456
101. Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature. Oon SF, Winter DC, J Med Screen 2010 17 1 44 49 10.1258/jms.2009.009058 20356945
102. Men's beliefs about HPV-related disease. Brewer NT, Ng TW, McRee AL, Reiter PL, J Behav Med 2010 33 274 281 10.1007/s10865-010-9251-2 20162346
103. Acceptability of prophylactic human papillomavirus vaccination among adult men. Hernandez BY, Wilkens LR, Thompson PJ, Shvetsov YB, Goodman MT, Ning L, Kaopua L, Hum Vaccine 2010 6 467 475 10.4161/hv.6.6.11279
104. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS, Sex Transm Dis 2010 37 197 203 10.1097/OLQ.0b013e3181bf542c 20118831
105. The cost-effectiveness of male HPV vaccination in the United States. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE, Vaccine 2011 29 46 8443 8450 10.1016/j.vaccine.2011.07.096 21816193
106. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J, BMC Cancer 2013 13 10 1 12 23282137
107. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK, Sex Transm Dis 2013 40 2 130 135 23324976
108. From an interview to harald Zur Hausen. Grayson M, Nature 2012 488 7413 16 10.1038/488S16a 22859180
109. Can male vaccination reduce burden of human papillomavirus-related disease in the United States? Low MI, Attiga YS, Garg G, Schelgal R, Gllicano GI, Viral Immunol 2012 25 3 174 183 22691099
110. European Centre for Disease Prevention and Control, Introduction of HPV vaccines in EU countries-an update Stockholm: ECDC 2012 978-92-9193-377-8 10.2900/60814 22015392
111. HPV vaccine for all. Michels KB, Zur Hausen H, Lancet 2009 374 9686 268 270 10.1016/S0140-6736(09)61247-2 19586657